For men with locally advanced prostate cancer, transdermal estradiol (tE2) patches are noninferior to luteinizing hormone-releasing hormone (LHRH) agonists as ...

Prostate cancer remains one of the most common diseases among men, yet current screening methods often lead to unnecessary ...

Transdermal estradiol (tE2) is an alternative to luteinizing hormone–releasing hormone (LHRH) agonists as androgen-deprivation therapy in patients with prostate cancer. With tE2, testosterone is ...

The first diagnostic procedures to detect prostate cancer have taken place in Dewsbury.

A phase 3 study found that transdermal oestradiol (tE2) patches were non-inferior to luteinising hormone-releasing hormone (LHRH) agonists for 3‑year metastasis‑free survival in patients with locally ...

Transdermal estradiol patches and LHRH agonists led to similar metastasis-free and overall survival in locally advanced prostate cancer. Estradiol was associated with substantially lower incidence of ...

We received back the results of Tom's Prostate Biopsy and they did identify cancer in 3/15 core samples taken. The doctors indicated that it was an intermediate grade cancer with a Gleason score of 7.

Women's HRT patches can treat prostate cancer just as effectively as standard hormone injections—but with fewer of the worst ...

Lung cancer is the leading cause of death from cancer. It kills more people in the U.S. than breast, prostate, and colon cancer combined. When lung adenocarcinoma, the most common primary lung cancer ...

Top cancer specialists are urging men to look past the common symptoms of aging and recognize these critical warning signs. It’s often said that if you have your health, you have everything, and there ...

Stereotactic breast biopsy needles have recently been placed on the medical device shortage list by FDA. The shortage could negatively impact Hologic, a company ranked 29th on MD+DI ’s Top 100 Medical ...